Ensho Health today announced the availability of sponsored screening for IL-1 mediated autoinflammatory diseases with the SD-9 algorithm to community rheumatologists participating in the IGNITE accredited learning program.
"Autoinflammatory disorders represent an acute diagnostic challenge" said Dr. Taha Bandukwala, Ensho Health Co-Founder and Chief Medical Officer. "They are diagnoses of exclusion whose symptoms overlap with common ailments like allergies and infections. We are thrilled to make the SD-9 algorithm available to participants in the IGNITE program. It's a terrific initiative led by an incredible faculty."
IGNITE is led by MedPlan ↗︎ of Montreal, Canada. The faculty consists of:
Participants will receive Section 3 Maintenance of Certification credits from the Royal College of Physicians and Surgeons of Canada.
About Ensho Health
Ensho Health is a health technology company whose mission is to empower healthcare providers to do more with data. It realizes its mission with solutions that improve patient outcomes and facilitate groundbreaking research. It operates clinical data labs that make machine learning and other clinically validated algorithms for early detection and individualized treatment of rare and complex diseases accessible to physicians and their patients, and provide information extraction services for secondary use of data studies with its Apollo aEDC system.